CA2572498A1 - Biphasic capsule formulation - Google Patents
Biphasic capsule formulation Download PDFInfo
- Publication number
- CA2572498A1 CA2572498A1 CA002572498A CA2572498A CA2572498A1 CA 2572498 A1 CA2572498 A1 CA 2572498A1 CA 002572498 A CA002572498 A CA 002572498A CA 2572498 A CA2572498 A CA 2572498A CA 2572498 A1 CA2572498 A1 CA 2572498A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical formulation
- release phase
- formulation according
- glyceride
- biphasic pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Capsule formulations are provided containing at least two different fill compositions which are prevented from mixing either by providing both of the fill compositions as solids or by providing a physical barrier which separates the fill compositions so that they are prevented from mixing. The invention has the advantage that two different formulations can be provided in a single capsule without one of the formulations having an adverse effect on the other.
Claims (6)
1. A biphasic pharmaceutical formulation comprising a solid rapid release phase and a solid sustained release phase, wherein said rapid release phase remains solid at a temperature below 30°C.
2. The biphasic pharmaceutical formulation according to claim 16, wherein the rapid release phase comprises a pharmaceutically active substance and a glyceride having a melting point above 30°C.
3. The biphasic pharmaceutical formulation according to claim 17, wherein the glyceride is a saturated polyglycolyzed glyceride.
4. The biphasic pharmaceutical formulation according to claim 17, wherein the glyceride is a hydrogenated fatty acid ester.
5. The biphasic pharmaceutical formulation according to claim 17, wherein the rapid release phase and the sustained release phase comprise a C12-C24 fatty acid.
6. The biphasic pharmaceutical formulation according to claim 20, wherein the C12-C24 fatty acid is oleic acid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9325445.6 | 1993-12-13 | ||
GB939325445A GB9325445D0 (en) | 1993-12-13 | 1993-12-13 | Pharmaceutical formulations |
CA002179041A CA2179041C (en) | 1993-12-13 | 1994-12-12 | Biphasic capsule formulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002179041A Division CA2179041C (en) | 1993-12-13 | 1994-12-12 | Biphasic capsule formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2572498A1 true CA2572498A1 (en) | 1995-06-22 |
CA2572498C CA2572498C (en) | 2010-07-13 |
Family
ID=37806595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2572498A Expired - Fee Related CA2572498C (en) | 1993-12-13 | 1994-12-12 | Biphasic capsule formulation |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2572498C (en) |
-
1994
- 1994-12-12 CA CA2572498A patent/CA2572498C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2572498C (en) | 2010-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE03425B1 (en) | Ciclosporin Preparations for Oral Administration with Simple Composition and High Bioavailability and Method of Preparation | |
CA2366754A1 (en) | Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants | |
CA2185347A1 (en) | A carrier for hydrophobic drugs and a pharmaceutical composition based thereon | |
HK1033263A1 (en) | Pharmaceutical compositions capable of being gelled | |
CA2383036A1 (en) | Solid lipid formulations | |
CA2376202A1 (en) | Novel preparation and administration form comprising an acid-labile active compound | |
CA2466868A1 (en) | Oral capsule formulation with increased physical stability | |
ATE152613T1 (en) | COMPOSITION WHICH FORMES A MICROEMULSION UPON PERORAL ADMINISTRATION | |
CA2137764A1 (en) | Pharmaceutical compositions comprising solutions or dispersions of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride | |
WO1999008666A3 (en) | Pharmaceutical composition comprising an azateroid | |
CA2572498A1 (en) | Biphasic capsule formulation | |
WO2001047497A3 (en) | Controlled release pharmaceutical composition containing tramadol hydrochloride | |
CA2203566A1 (en) | Percutaneously administration preparation | |
CA2197413C (en) | A pharmaceutical or veterinary composition | |
MY130474A (en) | Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |